The objective of this study was to evaluate characteristics that discriminate prolactinoma from non-functioning pituitary macroadenoma with hyperprolactinemia. We included 117 patients with hyperprolactinemic pituitary macroadenomas. Patients were divided into three groups according to treatment outcomes and pathologic results: (A) prolactinoma that responded to dopamine agonist (DA) treatment (PRDA); (B) prolactinoma requiring surgical treatment (PRS); and (C) non-functioning pituitary adenoma with hyperprolactinemia (NFPAH). Old age, low serum prolactin levels, and extrasellar extension were associated with NFPAH. Most patients with NFPAH had serum prolactin levels less than 100 ng/ml. Visual defects and GH deficiency were more common in ...
ABSTRACT Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they...
Aims and Objectives: To report hormonal outcome after surgery in a special subgroup of prolactinomas...
Objectives Macroprolactinomas are pituitary tumours that can be managed with dopamine agonists (DA),...
Dept. of Medical Science/석사[한글] [영문]The objective of this study was to evaluate characteristics tha...
Abstract: Objective: The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas...
In non-functioning pituitary macroadenoma (NFMA), hyperprolactinaemia (hyperPRL) is considered to be...
One form of prolactin (PRL) is macroprolactin with high molecular mass. Many macroprolactinemic pati...
Prolactinomas and non-functional adenomas are the most common types for pituitary adenoma. In patien...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...
Hyperprolactinemia occurs along with many physiological and non-physiological factors. The most impo...
Introduction. Approximately one third of pituitary adenomas are manifested neither by specific sympt...
This review focus on the epidemiology, diagnosis and treatment of prolactinomas. In particular, at...
Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represen...
OBJECTIVE: Prolactinoma and nonfunctioning adenoma (NFA) are the most common sellar pathologies, and...
Objective: The aim of the study was to evaluate clinical and laboratorial features of 1234 patients ...
ABSTRACT Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they...
Aims and Objectives: To report hormonal outcome after surgery in a special subgroup of prolactinomas...
Objectives Macroprolactinomas are pituitary tumours that can be managed with dopamine agonists (DA),...
Dept. of Medical Science/석사[한글] [영문]The objective of this study was to evaluate characteristics tha...
Abstract: Objective: The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas...
In non-functioning pituitary macroadenoma (NFMA), hyperprolactinaemia (hyperPRL) is considered to be...
One form of prolactin (PRL) is macroprolactin with high molecular mass. Many macroprolactinemic pati...
Prolactinomas and non-functional adenomas are the most common types for pituitary adenoma. In patien...
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention an...
Hyperprolactinemia occurs along with many physiological and non-physiological factors. The most impo...
Introduction. Approximately one third of pituitary adenomas are manifested neither by specific sympt...
This review focus on the epidemiology, diagnosis and treatment of prolactinomas. In particular, at...
Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represen...
OBJECTIVE: Prolactinoma and nonfunctioning adenoma (NFA) are the most common sellar pathologies, and...
Objective: The aim of the study was to evaluate clinical and laboratorial features of 1234 patients ...
ABSTRACT Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they...
Aims and Objectives: To report hormonal outcome after surgery in a special subgroup of prolactinomas...
Objectives Macroprolactinomas are pituitary tumours that can be managed with dopamine agonists (DA),...